Primary liver cancer is the third most deadly and fifth most common cancer worldwide (~500,000 deaths annually), with a sharp increase of incidence in the United States in recent years. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the major types of primary liver cancer. Risk factors include gender, hepatitis B virus (HBV), hepatitis C virus (HCV), cirrhosis, metabolism diseases, diabetes, obesity, toxins, excess alcohol consumption and smoking. Liver cancer arises most frequently in inflammatory livers with extensive oxidative stress due to viral hepatitis which causes over…mehr
Primary liver cancer is the third most deadly and fifth most common cancer worldwide (~500,000 deaths annually), with a sharp increase of incidence in the United States in recent years. Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) are the major types of primary liver cancer. Risk factors include gender, hepatitis B virus (HBV), hepatitis C virus (HCV), cirrhosis, metabolism diseases, diabetes, obesity, toxins, excess alcohol consumption and smoking. Liver cancer arises most frequently in inflammatory livers with extensive oxidative stress due to viral hepatitis which causes over 80% of HCC cases worldwide. Currently, survival remains dismal for most HCC and CC patients, largely due to the tumor's aggressiveness at the time of diagnosis and the lack of effective therapy. Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Artikelnr. des Verlages: 12545674, 978-1-4419-6081-8
2011
Seitenzahl: 416
Erscheinungstermin: 8. November 2010
Englisch
Abmessung: 241mm x 160mm x 27mm
Gewicht: 740g
ISBN-13: 9781441960818
ISBN-10: 1441960813
Artikelnr.: 28108479
Herstellerkennzeichnung
Books on Demand GmbH
In de Tarpen 42
22848 Norderstedt
info@bod.de
040 53433511
Inhaltsangabe
Part I: Introduction.- 1. Overview of HCC: biology and pathology.- Xin Wei Wang, Joe Grisham and Snorri Thorgeirsson.- 2. Overview of CC:.- Part II: Liver development and pathogenesis.- 3. Embryonic development of the liver.- Kenneth S. Zaret.- 4. Human hepatic cell lineages.- Nelson Fausto.- 5. Pathology of Human Liver Cancer.- Masamichi Kojiro.- Part III: Genetics and epidemiology of liver cancer.- 6. HCC.- Hashem El.Serag.- 7. CC.- Greg Gores.- Part IV: Molecular Basis of Cancer Susceptibility.- 8. Yusuke Nakamura (NCC).- 9. Hereditary liver diseases with a high risk to develop HCC.- Markus Grompe, [ALSO Marie-Annick Buendia].- 10. Genetics and epigenetics of preneoplastic liver diaseses and human HCC.- 11. HBV: Jack Wands.- 12. HCV: Stanly Lemon.- 13. Fibrosis and cirrhosis studies.- David Brenner .- 14. Methylation status in chronic liver disease and HCC.- Yae Kanai (Japan).- Part V. Animal models.- 15. Transgenic mouse models.- Snorri Thorgeirsson & Joe Grisham .- 16. Mosaic mouse model.- Scott Lowe.- 17. Zebrafish model.- Zhiyuan Gong (NUS): .- Part VI: Global gene expression profiling of human liver cancer.- 18. Integrative and functional genomics of HCC.- Snorri Thorgeirsson: .- 19. Molecular signatures of metastatic HCC .- Xin Wei Wang.- 20. Liver cancer heterogeneity and tumor subtypes.- Jessica Rossi.- 21. Gene expression studies in cholangiocarcinoma.- Yoichi Furokawa.- Part VII: Cancer stem cells.- 22. Snorri Thorgeirsson.- 23. Tania Roskams.- Part VIII: Liver cancer genetics in the clinic.- 24. Biomarkers and clinical staging of liver cancer.- Josep Llovet.- 25. Molecular signaling in HCC.- Hong Yang Wang (Shanghai).- 26. Molecular oncology and HCC.- Zhao-You Tang (Shanghai).- 27. Molecular pathogenesis of HCC.- Irene Ig (Hong Kong).
Part I: Introduction.- 1. Overview of HCC: biology and pathology.- Xin Wei Wang, Joe Grisham and Snorri Thorgeirsson.- 2. Overview of CC:.- Part II: Liver development and pathogenesis.- 3. Embryonic development of the liver.- Kenneth S. Zaret.- 4. Human hepatic cell lineages.- Nelson Fausto.- 5. Pathology of Human Liver Cancer.- Masamichi Kojiro.- Part III: Genetics and epidemiology of liver cancer.- 6. HCC.- Hashem El.Serag.- 7. CC.- Greg Gores.- Part IV: Molecular Basis of Cancer Susceptibility.- 8. Yusuke Nakamura (NCC).- 9. Hereditary liver diseases with a high risk to develop HCC.- Markus Grompe, [ALSO Marie-Annick Buendia].- 10. Genetics and epigenetics of preneoplastic liver diaseses and human HCC.- 11. HBV: Jack Wands.- 12. HCV: Stanly Lemon.- 13. Fibrosis and cirrhosis studies.- David Brenner .- 14. Methylation status in chronic liver disease and HCC.- Yae Kanai (Japan).- Part V. Animal models.- 15. Transgenic mouse models.- Snorri Thorgeirsson & Joe Grisham .- 16. Mosaic mouse model.- Scott Lowe.- 17. Zebrafish model.- Zhiyuan Gong (NUS): .- Part VI: Global gene expression profiling of human liver cancer.- 18. Integrative and functional genomics of HCC.- Snorri Thorgeirsson: .- 19. Molecular signatures of metastatic HCC .- Xin Wei Wang.- 20. Liver cancer heterogeneity and tumor subtypes.- Jessica Rossi.- 21. Gene expression studies in cholangiocarcinoma.- Yoichi Furokawa.- Part VII: Cancer stem cells.- 22. Snorri Thorgeirsson.- 23. Tania Roskams.- Part VIII: Liver cancer genetics in the clinic.- 24. Biomarkers and clinical staging of liver cancer.- Josep Llovet.- 25. Molecular signaling in HCC.- Hong Yang Wang (Shanghai).- 26. Molecular oncology and HCC.- Zhao-You Tang (Shanghai).- 27. Molecular pathogenesis of HCC.- Irene Ig (Hong Kong).
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826